dcc-3084
dcc-3084: sourced relationships with 1 company · 1 clinical trial tracked.
dcc-3084 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could dcc-3084 → DCPH affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Primary endpoint: Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1)
Frequently asked questions
Which companies have sourced relationships with dcc-3084?
dcc-3084 has dated SEC/FDA relationship records for Deciphera Pharmaceuticals, Inc..
How many clinical trials involve dcc-3084?
BioSniper tracks 1 clinical trial involving dcc-3084.